Bosentan Therapy for Inoperable Chronic Thromboembolic Pulmonary Hypertension
Bosentan Therapy for Inoperable Chronic Thromboembolic Pulmonary Hypertension
About this item
Full title
Author / Creator
Publisher
Northbrook, IL: Elsevier Inc
Journal title
Language
English
Formats
Publication information
Publisher
Northbrook, IL: Elsevier Inc
Subjects
More information
Scope and Contents
Contents
We performed an open-label multicenter study to evaluate the safety and efficacy of the dual endothelin receptor antagonist bosentan in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH).
Nineteen patients with inoperable CTEPH were enrolled.
The primary end point was a change in pulmonary vascular resistance (PVR)...
Alternative Titles
Full title
Bosentan Therapy for Inoperable Chronic Thromboembolic Pulmonary Hypertension
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_68706520
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_68706520
Other Identifiers
ISSN
0012-3692
E-ISSN
1931-3543
DOI
10.1378/chest.128.4.2363
